-
21.发明授权公开(公告)号：US09242975B2
公开(公告)日：2016-01-26
申请号：US14371456
申请日：2013-01-11
Applicant: Bristol-Myers Squibb Company
Inventor： Venkatram Reddy Paidi , Sreekantha Ratna Kumar , Abhisek Banerjee , Ramesh Sistla , Satheesh Kesavan Nair , William J. Pitts , John Hynes
IPC: C07D417/14 , C07D413/14 , C07D413/04 , C07D417/04 , C07D471/04 , C07D471/10 , C07D487/04
CPC classification number: C07D417/14 , C07D413/04 , C07D413/14 , C07D417/04 , C07D471/04 , C07D471/10 , C07D487/04
Abstract: Compounds having the following formula: wherein A is, or; and X is N or C—R7, or an enantiomer, diastereomer or a pharmaceutically-acceptable salt thereof, are useful as kinase modulators, including IRAK-4 modulation.
Abstract translation: 具有下式的化合物：其中A是或; 并且X是N或C-R7，或其对映体，非对映体或其药学上可接受的盐，可用作激酶调节剂，包括IRAK-4调节。
-
22.发明申请IMIDAZOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES 有权咪达唑啶酮JAK3抑制剂及其用于治疗炎症和自发性疾病的用途公开(公告)号：US20150210703A1
公开(公告)日：2015-07-30
申请号：US14426625
申请日：2013-09-05
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Bingwei Vera Yang , Gregory D. Brown , Arun Kumar Gupta , William J. Pitts
IPC: C07D487/04
CPC classification number: C07D487/04 , C07B59/002 , C07B2200/05
Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of JAK3, thereby making them useful for the treatment of inflammatory and autoimmune diseases.
Abstract translation: 本发明提供式（I）化合物及其药学上可接受的盐。 式I化合物抑制JAK3的酪氨酸激酶活性，从而使其可用于治疗炎症和自身免疫性疾病。
-
公开(公告)号：US12172975B2
公开(公告)日：2024-12-24
申请号：US17274220
申请日：2019-09-12
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Junqing Guo , Jie Chen , Carolyn Diane Dzierba , Amy C. Hart , Guanglin Luo , John E. Macor , William J. Pitts , Sing-Yuen Sit
IPC: C07D401/04 , C07D401/14 , C07D405/14
Abstract: Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, (I) are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.
-
公开(公告)号：US20210309633A1
公开(公告)日：2021-10-07
申请号：US17274227
申请日：2019-09-12
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Junqing Guo , Carolyn Diane Dzierba , Amy C. Hart , John E. Macor , William J. Pitts
IPC: C07D401/04 , C07D403/04 , C07D413/04 , C07D401/14 , C07D413/14
Abstract: Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.
-
公开(公告)号：US10544133B2
公开(公告)日：2020-01-28
申请号：US16009389
申请日：2018-06-15
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Rajeev S. Bhide , John V. Duncia , John Hynes , Satheesh Kesavan Nair , William J. Pitts , Sreekantha Ratna Kumar , Daniel S. Gardner , Natesan Murugesan , Venkatram Reddy Paidi , Joseph B. Santella , Ramesh Kumar Sistla , Hong Wu
IPC: C07D407/14 , C07D401/14 , C07D401/12 , C07D417/14 , C07D213/74 , C07D405/12 , C07D405/14
Abstract: Compounds having the following formula: or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein R2 is a monocyclic heteroaryl group, and R1, R3, R4, R5 and R6 are as defined herein, are useful as kinase modulators, including IRAK-4 inhibition.
-
Patent Agency Ranking
公开(公告)号：US20190389859A1
公开(公告)日：2019-12-26
申请号：US16484604
申请日：2018-02-12
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Junqing Guo , Amy C. Hart , John E. Macor , Michael E. Mertzman , William J. Pitts , Steven H. Spergel , Scott Hunter Watterson , Murugaiah Andappan Murugaiah Subbaiah , Jie Chen , Carolyn Diane Dzierba , Guanglin Luo , Jianliang Shi , Sing-Yuen Sit
IPC: C07D471/04
Abstract: Compounds having formula (I) (IX), and enantiomers, and diastereomers, stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein: (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX).
-
公开(公告)号：US09862715B2
公开(公告)日：2018-01-09
申请号：US14960785
申请日：2015-12-07
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Venkatram Reddy Paidi , Sreekantha Ratna Kumar , Abhisek Banerjee , Ramesh Sistla , Satheesh Kesavan Nair , William J. Pitts , John Hynes
IPC: C07D417/04 , C07D417/14 , C07D413/14 , C07D413/04 , C07D471/04 , C07D487/04
CPC classification number: C07D417/14 , C07D413/04 , C07D413/14 , C07D417/04 , C07D471/04 , C07D487/04
Abstract: Compounds having the following formula: or an enantiomer, diastereomer or a pharmaceutically-acceptable salt thereof, wherein X is N or C—R7, are useful as kinase modulators, including IRAK-4 modulation.
-
28.发明授权Thiazolyl- or thiadiazolyl-substituted pyridyl compounds useful as kinase inhibitors 有权可用作激酶抑制剂的噻唑基或噻二唑基取代的吡啶基化合物公开(公告)号：US09242976B2
公开(公告)日：2016-01-26
申请号：US14371463
申请日：2013-01-11
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Venkatram Reddy Paidi , Sreekantha Ratna Kumar , Abhisek Banerjee , Ramesh Sistla , Satheesh Kesavan Nair , William J. Pitts , John Hynes
IPC: C07D417/14 , C07D413/14 , C07D413/04 , C07D417/04 , C07D471/04 , C07D487/04
CPC classification number: C07D417/14 , C07D413/04 , C07D413/14 , C07D417/04 , C07D471/04 , C07D487/04
Abstract: Compounds having the following formula (I) or an enantiomer, diastereomer or a pharmaceutically-acceptable salt thereof, wherein X is N or C—R7, are useful as kinase modulators, including IRAK-4 modulation.
Abstract translation: 具有下式（I）的化合物或其对映体，非对映异构体或其药学上可接受的盐，其中X为N或C-R7，可用作激酶调节剂，包括IRAK-4调节。
-
29.发明申请THIAZOLYL- OR THIADIAZOLYL-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE INHIBITORS 有权作为激酶抑制剂有用的三唑基或噻二唑基取代的吡啶化合物公开(公告)号：US20150018344A1
公开(公告)日：2015-01-15
申请号：US14371463
申请日：2013-01-11
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Venkatram Reddy Paidi , Sreekantha Ratna Kumar , Abhisek Banerjee , Ramesh Sistla , Satheesh Kesavan Nair , William J. Pitts , John Hynes
IPC: C07D417/14 , C07D417/04
CPC classification number: C07D417/14 , C07D413/04 , C07D413/14 , C07D417/04 , C07D471/04 , C07D487/04
Abstract: Compounds having the following formula (I) or an enantiomer, diastereomer or a pharmaceutically-acceptable salt thereof, wherein X is N or C—R7, are useful as kinase modulators, including IRAK-4 modulation.
Abstract translation: 具有下式（I）的化合物或其对映体，非对映异构体或其药学上可接受的盐，其中X为N或C-R7，可用作激酶调节剂，包括IRAK-4调节。
-
公开(公告)号：US12240840B2
公开(公告)日：2025-03-04
申请号：US17289269
申请日：2019-10-28
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Steven H. Spergel , William J. Pitts , Michael E. Mertzman , Ryan M. Moslin , Trevor C. Sherwood , John L. Gilmore , Alaric J. Dyckman
IPC: C07D413/14 , C07B59/00 , C07D401/14 , C07D403/12 , C07D403/14 , C07D413/12 , C07D417/12 , C07D417/14
Abstract: Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition.
-
-
-
-
-
-
-
-
-
Search Results
38
records
(took 0.042 seconds)
